Monday, October 1, 2012
Current Length of Herceptin Cancer Treatment Is Supported by Studies - New York Times
Moneycontrol.comCurrent Length of Herceptin Cancer Treatment Is Supported by StudiesNew York TimesEven as Herceptin has become a hugely successful breast cancer drug, doctors have been troubled by a nagging question that has billion-dollar implications: how long should patients be treated with it? Now the results of two closely watched studies ...Cancer trials show one year on Roche's Herceptin is bestReutersNew findings on optimal duration of trastuzumab therapy for women with HER2+
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment